A 2-year study shows potential utility of a novel lesion-imaging modality.
MRI with gadolinium contrast can differentiate acutely active from nonacute lesions but does not provide information about chronic lesions. In this study, investigators used a translocator protein radiotracer, [18F]-DPA-714-PET, to classify T2-weighted lesions based on inflammatory profile. White-matter lesions were classified as homogeneously active, rim-active, or nonactive. Included were 36 patients with MS (mean disease duration, 9 years), 12 with relapsing-remitting and 24 with progressive disease. PET imaging was done at baseline. Clinical assessments and MRI were conducted at baseline and 2 years.
Of 1335 T2-weighted lesions, 53% were homogeneously active, 6% rim-active, and 41% nonactive at baseline. On average, each patient had 20 h…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)